Move on HPV vaccine rollout to adolescent girls raises other vaccination priorities for Kerala: epidemiologists
Going by the current data from the population-based and hospital-based cancer registries in Kerala, the incidence of cervical cancer has been on a steady decline in the State over the past several years and it no longer figures among the top five cancers affecting women in Kerala, according to epidemiologists. This is consistent with improvements in women's health and hygiene, better sexual practices, education and healthcare access in Kerala.
Even though the World Health Organization (WHO) has recommended HPV vaccination for adolescent girls, in Kerala cervical cancer incidence is only eight per lakh population, even when at the national level, cervical cancer remained the second highest of all cancers reported amongst women as in 2022.
'Only if there is an uptick'
The committee headed by Dr. B. Ekbal, which submitted the State's Vaccine Policy recommendations in November 2022, had noted that HPV vaccination should be considered in Kerala only if there is an increasing trend in the incidence of cervical cancer from the current baseline.
It said that given the fact that the cost of vaccinating 13 lakh adolescent girls would be over ₹200 crore, HPV vaccination was not indicated, nor was it cost effective.
Dr. Ekbal says that this picture has changed given that Serum Institute of India is now producing HPV vaccines at much competitive rates. While HPV vaccine manufactured by pharma majors are available in the range of ₹2,000-₹4,000/dose (there is also the HPV vaccine which protects against nine strains of HPV, costing around ₹10,850/dose), Cervavac produced by Serum Institute of India is available at ₹2,000/dose.
'HPV vaccine cost has come down and as far as dosage is concerned, there is some emerging evidence, (as per the WHO), that even a single dose delivers solid protection against HPV. That changes the picture completely. From a gender perspective, I am happy about the State's decision to protect adolescent girls against HPV,' Dr. Ekbal said.
Current public health concerns
However, the State should not forget its current public health concerns, which included protecting children from rabies through anti-rabies pre-exposure prophylaxis vaccine and from mumps, through an additional dose of MMR vaccine, he said. Rabies is emerging as a serious public health issue in the State, with children being a major casualty, he reminded.
'The mortality and morbidity due to influenza and pneumococcal infections is high in the elderly, the immunocompromised and those with co-morbidities. The State should prioritise annual flu vaccine and pneumococcal vaccine to protect elderly against pneumonia and meningitis,' Dr. Ekbal pointed out.
He said that the Health department should recommend these vaccines so that there is more uptake for the same, which can bring down the cost of vaccines.
Time to push for elimination
'Introducing HPV for adolescent girls is a policy decision that the Government had taken much earlier. Questions whether HPV vaccination is a priority now can be controversial. It is true that cervical cancer incidence is going down steadily and thus this would be the right time to push through elimination strategies. HPV vaccination is being introduced as part of the State's efforts to eliminate cervical cancer and the operational details are being worked out,' PK Jameela, member, State Planning Board, said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
an hour ago
- NDTV
WHO Advises Against The Use Of Antibiotics For COVID-19 Patients
New Delhi: The World Health Organisation (WHO) has advised against the use of antibiotics even in patients with severe COVID when a concurrent bacterial infection is not suspected. The global health body has released updated recommendations for the clinical management of people with COVID, which, it said, are based on evidence generated from a recent meta-analysis of outcomes of patients treated with antibiotics for the virus. "For patients with non-severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we recommend no empirical antibiotics. For patients with severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we suggest no empirical antibiotics," the WHO said. The WHO said that, as COVID-19 epidemiology and severity have changed, and as emergency measures have subsided, the evidence behind a number of recommendations has changed. In parallel, the evolution of health systems and the global environment has meant that the recommendations are implemented in a very different context in 2024 compared to 2020. These guidelines have evolved from the first version in 2020 in line with new information and changing circumstances of the pandemic, the WHO said. "Notable changes to COVID-19 disease over this time have been overall reduced infection rates and reduced disease severity. Emergency measures which were imposed have also been removed, and care for patients with COVID-19 has become more integrated with usual healthcare systems. "This different environment has prompted a review of the scope and content of all existing guidance. In order to maintain a clear focus and relevance, we have removed recommendations which would be considered general medical principles, and those which are no longer specific to the management of COVID-19," the WHO said. The new recommendations on the use of antibiotics were prompted by the publication of data from a systematic review and meta-analysis, and the pressing need to address antimicrobial resistance. The WHO said the updated guidelines are for people directly or indirectly involved in the health care of patients with COVID-19 and post-COVID-19 conditions. This includes clinicians, allied health care workers, facility managers, and hospital administrators. The SARS-CoV-2 continues to infect several thousand people daily, leading to preventable morbidity and mortality across the world, the WHO said. The roll-out of vaccines and treatment for COVID-19, and increasing population immunity from infection, has substantially reduced hospitalization, severity of disease, and mortality. "However, the virus continues to evolve in terms of infectivity, immune escape, and disease severity. This guideline robustly and transparently addresses the changing landscape and evidence availability, and the continual development of treatment and management strategies for COVID-19," the WHO stated.
Time of India
4 hours ago
- Time of India
Bowel cancer on the rise: Experts reveal the hidden factor that increases the risk of colorectal cancer
A recent study by Flinders University reveals a significant link between having both adenomas and serrated polyps in the bowel and an increased risk of developing colorectal cancer. Individuals with these synchronous lesions are five times more likely to develop advanced pre-cancerous changes. Bowel cancer, also known as colorectal cancer, is the third most common cancer and the second leading cause of cancer-related deaths worldwide, according to the World Health Organization ( WHO ). What makes this cancer particularly dangerous is that the symptoms don't appear in early stages, which delays diagnosis and drastically reduces treatment outcomes. Experts now think that common growth can significantly increase the risk of bowel cancer. A new study conducted by the researchers at Flinders University and Flinders Medical Centre has found a critical link between having two types of polyps, common growths found in the bowel, and an increased risk of developing cancer. The findings of the study are published in the Clinical Gastroenterology and Hepatology (CGH) journal. Bowel cancer and common growths Most of the bowel cancers begin as benign polys, which are non-threatening growths that appear on the wall or the lining of the bowel. There are two types of polyps - adenomas and serrated polyps, which can progress into cancer. To understand if these common growths could increase cancer risk, the researchers analyzed over 8,400 colonoscopy records. They found that people with both adenomas and serrated polyps were up to five times more likely to develop advanced pre-cancerous changes than those with just one type. 'Polyps are common and usually harmless, but when both types appear together—what we call synchronous lesions—the risk of serious bowel disease or cancer rises sharply,' Dr Molla Wassie, lead author and researcher at the FHMRI Bowel Health Service, said in a statement. What's more concerning is that nearly half of all the patients with serrated polyps also had adenomas, which hints that the high-risk group is more common than previously thought. 'This is one of the largest studies of its kind. Our findings support growing international evidence that these two types of polyps may represent separate cancer pathways that can be active at the same time, making early detection and regular monitoring even more important,' Dr. Wassie said. The researchers also noticed that serrated polyps may progress to cancer faster than adenomas. 'Polyps become more common as we age, but the key is catching and removing them early. If you've had both types of polyps, it's especially important to stay on top of your colonoscopy schedule. If you're over 45 or have a family history of bowel issues, talk to your GP or visit the National Bowel Cancer Screening Program to learn more,' Dr Wassie added. No more guesswork: Doctor busts common myths about women's health What are the symptoms of bowel cancer ? Though bowel cancer does not have symptoms in the early stages, regular screening can help catch the disease early. Some of the common symptoms include: Changes in bowel habits (diarrhoea, constipation, or narrowing of the stool) Rectal bleeding Abdominal pain, cramps, or bloating that persists Unexplained weight loss Chronic fatigue Factors such as age, family history, personal history, and lifestyle factors (diet high in processed meats and low in fruits and vegetables, sedentary behaviour, obesity, smoking, excessive alcohol consumption) may increase the risk.
Time of India
4 hours ago
- Time of India
How Hepatitis D virus can cause liver cancer: Know its symptoms, risks, causes, and more
The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) have officially classified the Hepatitis D virus (HDV) as carcinogenic to humans. This places HDV alongside Hepatitis B and Hepatitis C as major causes of liver cancer. The reclassification is based on increasing evidence of HDV's severe health risks, especially its role in accelerating liver damage and cancer in co-infected individuals. This important update emphasises the urgent need for better awareness, expanded testing, and improved treatment options to combat HDV and reduce the global burden of liver cancer and liver-related deaths. Understanding Hepatitis D Virus (HDV) and its symptoms Hepatitis D is a unique and dangerous virus that requires the presence of Hepatitis B virus (HBV) to infect and replicate. HDV cannot infect people on its own; it "hijacks" the HBV infection process, resulting in more severe liver disease when both viruses coexist. Symptoms of HDV infection often overlap with other liver diseases and can be easily overlooked. Common signs include: Fatigue and weakness Nausea and loss of appetite Abdominal pain or discomfort, especially in the upper right side Dark-coloured urine Yellowing of the skin and eyes (jaundice) Unexplained weight loss Fever Because symptoms may be mild or mistaken for other illnesses, many individuals delay seeking medical care, increasing the risk of serious liver damage. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Signs Of Heart Attack That Shouldn't Be Ignored (Take A Look) TheDaddest Undo What causes Hepatitis D virus infection HDV spreads primarily through direct contact with infected blood or bodily fluids. Common modes of transmission include: Infected blood transfusions or blood products Unprotected sexual contact with an infected person Sharing needles or syringes among people who inject drugs Unsafe medical procedures involving non-sterile equipment Mother-to-child transmission during childbirth (less common) Because HDV can only infect individuals already carrying HBV, anyone with chronic hepatitis B is at risk of contracting HDV. Who is at risk of Hepatitis D Infection Populations at higher risk for HDV infection include: People living in regions with high HBV prevalence such as parts of Asia, Africa, and the Amazon Basin People who inject drugs and share needles Patients receiving haemodialysis or undergoing frequent blood transfusions Individuals with multiple sexual partners or those who engage in unprotected sex Infants born to mothers infected with both HBV and HDV Awareness and screening in these groups are essential for early detection Global impact: How widespread is Hepatitis D According to the WHO, over 300 million people worldwide are infected with hepatitis B, C, or D, contributing to about 1.3 million deaths annually, mostly from liver cirrhosis and liver cancer. About 5% of chronic HBV carriers, roughly 12 million people worldwide, are co-infected with HDV. Why is Hepatitis D considered dangerous Co-infection with HDV dramatically worsens liver health outcomes. Research shows: HDV increases the risk of liver cancer by two to six times compared with HBV infection alone. Up to 75% of chronic HDV patients develop liver cirrhosis within 15 years, which is significantly higher than HBV-only cases. HDV accelerates liver inflammation and damage, raising the risk of severe complications and death. Current treatment options for Hepatitis D While chronic HBV infection can be managed with lifelong antiviral therapies, treatment options for HDV are limited but improving: Bulevirtide: Approved in Europe, this antiviral helps block HDV entry into liver cells, improving outcomes, especially when combined with pegylated interferon. Pegylated interferon: Sometimes used to suppress HDV replication, but effectiveness varies. No specific hepatitis D vaccine exists; prevention depends on hepatitis B vaccination, which protects against both HBV and HDV infections. Progress in global hepatitis B vaccination and testing Vaccination remains the most effective prevention method. As of 2025: 129 countries have adopted hepatitis B testing for pregnant women (up from 106 in 2024). 147 countries provide the hepatitis B birth dose vaccine (up from 138 in 2022). These efforts are critical to preventing HBV and consequently HDV transmission. Expert recommendations to combat Hepatitis D To achieve WHO's hepatitis elimination goals by 2030, health authorities must: Scale up hepatitis B vaccination coverage worldwide Ensure universal testing of HBV-positive individuals for HDV Expand access to novel HDV therapies and affordable medicines Strengthen healthcare infrastructure and data systems Combat stigma and discrimination around viral hepatitis to encourage testing and treatment Meeting these goals could save 2.8 million lives and prevent 9.8 million new infections by 2030. Also read | Testicular cancer symptoms men often miss: Know the risks, treatment options, and what to watch for
